Samsung Biologics signed an acquisition agreement with PolyPeptide Group on the 20th for approximately 2.7 trillion won. The deal represents the largest merger and acquisition in Korea's pharmaceutical and biotechnology industry. Samsung Biologics plans to acquire 100% equity through majority shareholder acquisition and public tender offer, with completion targeted by the end of December this year. The acquisition expands Samsung Biologics' service portfolio beyond antibody drugs, mRNA, and antibody-drug conjugates into the high-growth peptide pharmaceutical sector, diversifying its business portfolio and securing mid-to-long-term growth drivers.
Samsung Biologics Acquires PolyPeptide Group for 2.7 Trillion Won
Samsung Biologics announced the signing of an acquisition agreement with PolyPeptide Group on the 20th. The acquisition amount totals approximately 2.7 trillion won, making it the largest M&A transaction in Korea's pharmaceutical and biotechnology industry according to the company. Samsung Biologics will secure 100% equity stake in PolyPeptide Group through majority shareholder acquisition and public tender offer. The company plans to complete the acquisition by the end of December this year. Samsung Biologics will inherit ongoing CDMO contracts performed by PolyPeptide Group, enabling continuity of order volume immediately following the acquisition.
Peptide Pharmaceuticals Drive GLP-1 Obesity and Diabetes Treatment Growth
Peptides are substances formed by short chain-like connections of amino acids, the basic building blocks of proteins. They perform messenger roles in the body by transmitting hormones or signals between cells. Peptide pharmaceuticals are developed by artificially synthesizing these substances for disease treatment. GLP-1 (glucagon-like peptide-1) class drugs for obesity and diabetes treatment represent prominent examples of the expanding peptide market. Global pharmaceutical companies are extending peptide pipelines beyond obesity and diabetes into anticancer, immune disease, and brain disease treatment areas.
PolyPeptide Group Operates Global CDMO Network Since 1996
PolyPeptide Group is a peptide CDMO specialist company spun off from global pharmaceutical company Ferring's peptide production division in 1996. The company is headquartered in Baar, Switzerland. PolyPeptide Group operates as a dedicated contract development and manufacturing organization focused exclusively on peptide therapeutics.
Samsung Biologics Expands Three Strategic Growth Pillars
John Rim, CEO of Samsung Biologics, stated that this acquisition represents a strategic decision encompassing all three growth pillars of Samsung Biologics: production capacity, business portfolio, and global presence. Rim added that the company will strengthen competitiveness in the global CDMO market. The acquisition enables Samsung Biologics to expand its service business from existing antibody drugs, mRNA, and ADC focus into the recently high-growth peptide sector.
FAQ
What did Samsung Biologics acquire on the 20th?
Samsung Biologics signed an acquisition agreement with PolyPeptide Group on the 20th for approximately 2.7 trillion won, representing the largest M&A deal in Korea's pharmaceutical and biotechnology industry. The company plans to acquire 100% equity stake through majority shareholder acquisition and public tender offer, with completion targeted by the end of December this year.
What are peptide pharmaceuticals and why are they significant?
Peptides are substances formed by short chain-like connections of amino acids that perform messenger roles in the body. Peptide pharmaceuticals are artificially synthesized versions developed for disease treatment. GLP-1 class drugs for obesity and diabetes treatment exemplify the expanding peptide market, with global pharmaceutical companies extending pipelines into anticancer, immune disease, and brain disease treatment areas.
